Early observations and pilot data that first suggested a new direction
The MAGIC trial (2006) established perioperative chemotherapy as a standard for resectable gastroesophageal cancer. Among 503 patients randomized to perioperative ECF (epirubicin, cisplatin, fluorouracil) plus surgery versus surgery alone, perioperative chemotherapy improved 5-year overall survival from 23% to 36% (HR 0.75, 95% CI 0.60-0.93, p=0.009). Although primarily a gastric cancer trial (74% gastric), it included esophagogastric junction and lower esophageal tumors, providing the first randomized evidence for neoadjuvant treatment in this disease.
Landmark RCTs and pivotal trials that established the evidence base
The CROSS trial (2012) transformed the treatment of esophageal cancer by demonstrating the superiority of neoadjuvant chemoradiation over surgery alone. Among 368 patients randomized to weekly carboplatin/paclitaxel with 41.4 Gy radiotherapy followed by surgery versus surgery alone, neoadjuvant chemoradiation achieved a 29% pathologic complete response rate and improved median overall survival from 24 to 48.6 months. At 10-year follow-up, the absolute survival benefit was 13% (38% vs 25%), with a hazard ratio of 0.60 for esophageal cancer-related death. The CROSS regimen became the global standard for neoadjuvant treatment.
Follow-up studies, subgroup analyses, and real-world validation
CheckMate 577 (2021) introduced adjuvant immunotherapy following neoadjuvant chemoradiation and surgery. Among 794 patients with residual pathologic disease (non-pCR) after neoadjuvant CRT and R0 resection, adjuvant nivolumab doubled median disease-free survival compared to placebo (22.4 vs 11.0 months; HR 0.69, p<0.001). This trial added a critical component to the treatment pathway for patients who did not achieve pathologic complete response, establishing a new standard of neoadjuvant CRT followed by surgery followed by adjuvant nivolumab for non-complete responders.
Integration into clinical practice guidelines and recommendations
The CROSS regimen is the standard neoadjuvant treatment for resectable esophageal and GEJ cancer globally. Adjuvant nivolumab (CheckMate 577) is recommended for patients with residual disease after neoadjuvant CRT and surgery. Perioperative FLOT chemotherapy (without radiation) is an alternative for GEJ adenocarcinoma based on the FLOT4 trial.
NCCN
Neoadjuvant chemoradiation (CROSS) followed by surgery; adjuvant nivolumab for non-pCR patients
ESMO
CROSS neoadjuvant CRT standard; perioperative FLOT acceptable for GEJ adenocarcinoma; adjuvant nivolumab for residual disease
Now
Current standard of care and ongoing research directions
The treatment paradigm for esophageal cancer has evolved from surgery alone to a multimodal approach incorporating neoadjuvant chemoradiation (CROSS), surgery, and adjuvant immunotherapy (CheckMate 577). Active research frontiers include neoadjuvant immunotherapy-chemotherapy-radiation combinations (KEYNOTE-590, CheckMate 648 in the neoadjuvant setting), personalized treatment based on ctDNA response assessment, and organ preservation strategies for clinical complete responders (analogous to the watch-and-wait approach in rectal cancer).
What is the standard neoadjuvant treatment for esophageal cancer?+
The CROSS trial (368 patients) established neoadjuvant chemoradiation (weekly carboplatin/paclitaxel with 41.4 Gy radiation) followed by surgery as the global standard. This approach improved median overall survival from 24 to 48.6 months and 10-year survival from 25% to 38%. For patients with residual disease after surgery, CheckMate 577 (794 patients) showed that adjuvant nivolumab doubled disease-free survival (22.4 vs 11.0 months).
How does CheckMate 577 change the treatment pathway?+
CheckMate 577 demonstrated that patients who did not achieve pathologic complete response after neoadjuvant CRT and surgery benefited from 1 year of adjuvant nivolumab (DFS: 22.4 vs 11.0 months, HR 0.69). This added a critical post-surgical component to the treatment pathway for the approximately 70% of patients with residual disease after neoadjuvant treatment.
